Pfizer Discontinues Two Phase III Primary Care Projects
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is halting development of treatments for generalized anxiety disorder and fibromyalgia.
You may also be interested in...
Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.